Signal transducer and activator of transcription (STAT) proteins are implic
ated in the control of cell survival., proliferation and differentiation in
response to hematopoietic cytokines. C-terminally truncated STAT isoforms
(STAT beta), as opposed to the full length form (STAT alpha), have a compet
itive or even transdominant negative effect on gene induction mediated by t
he STAT pathway. We have previously demonstrated that while constitutively
active STAT proteins were detected in ten of 36 (28%) for STAT3 and eight o
f 36 (22%) for STAT5 in pretreatment samples from newly diagnosed acute mye
loid leukemia (AML) patients, a significantly larger fraction of samples [2
1 of 27 (78%)] expressed STAT beta proteins. To determine whether STAT beta
expression was maintained or increased after relapse in AML, we compared S
TAT activity and isoform expression at diagnosis and at relapse in 17 patie
nts. In this selected group, constitutively active STAT3 was detected in 13
of 17 (76%) AML samples at diagnosis but was detected in only four of thes
e patients at relapse, Constitutively active STAT5 was detected in three of
17 (18%) AML samples at diagnosis; but only two at relapse. In contrast. S
TAT beta protein expression was observed in 12 of the 17 pretreatment sampl
es (71%) and in 16 of 17 samples at relapse. Only one patient did not expre
ss STAT beta at relapse. Our results suggest that STAT beta isoform express
ion, rather than level of constitutive activity, may be involved in disease
progression in AML. (C) 2001 Elsevier Science Ltd. All rights reserved.